{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:15:13Z","timestamp":1773418513369,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.ghir.2015.07.002","type":"journal-article","created":{"date-parts":[[2015,7,11]],"date-time":"2015-07-11T05:02:24Z","timestamp":1436590944000},"page":"240-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations"],"prefix":"10.1016","volume":"25","author":[{"given":"A.","family":"Ciresi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pizzolanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ghir.2015.07.002_bb0005","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1210\/endo-83-2-300","article-title":"Multiple effects of growth hormone on lipolysis","volume":"83","author":"Goodman","year":"1968","journal-title":"Endocrinology"},{"key":"10.1016\/j.ghir.2015.07.002_bb0010","first-page":"717","article-title":"Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human","volume":"19","author":"Giustina","year":"1998","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ghir.2015.07.002_bb0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1023321421760","article-title":"Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly","volume":"5","author":"Clemmons","year":"2002","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2015.07.002_bb0020","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1210\/jc.2012-1518","article-title":"Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients","volume":"97","author":"Ciresi","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0025","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2007-2780","article-title":"Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly","volume":"93","author":"Freda","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0030","article-title":"The metabolic risk in newly diagnosed patients with acromegaly is related to fat distribution and circulating adipokines and improves after treatment","author":"Olarescu","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ghir.2015.07.002_bb0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/EJE-13-0523","article-title":"Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities","volume":"170","author":"Olarescu","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2015.07.002_bb0040","doi-asserted-by":"crossref","first-page":"E827","DOI":"10.1152\/ajpendo.2001.280.6.E827","article-title":"The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation","volume":"280","author":"Fr\u00fchbeck","year":"2001","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0045","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/en.2003-1336","article-title":"Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans","volume":"145","author":"Fain","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.ghir.2015.07.002_bb0050","doi-asserted-by":"crossref","first-page":"393192","DOI":"10.1155\/2013\/393192","article-title":"Adipose tissue dysfunction in nascent metabolic syndrome","volume":"2013","author":"Bremer","year":"2013","journal-title":"J. Obes."},{"key":"10.1016\/j.ghir.2015.07.002_bb0055","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1210\/er.2006-0033","article-title":"Adipose tissue-derived factors: impact on health and disease","volume":"27","author":"Trujillo","year":"2006","journal-title":"Endocr. Rev."},{"issue":"2010","key":"10.1016\/j.ghir.2015.07.002_bb0060","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1210\/jc.2009-2670","article-title":"A consensus on criteria for cure of acromegaly","volume":"95","author":"Giustina","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0065","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.ghir.2015.07.002_bb0070","first-page":"460","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"24","author":"Matsuda","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ghir.2015.07.002_bb0075","first-page":"E214","article-title":"Glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"DeFronzo","year":"1979","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ghir.2015.07.002_bb0080","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/dc09-1825","article-title":"Visceral adiposity index (VAI): a reliable indicator of visceral fat function associated with cardiometabolic risk","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ghir.2015.07.002_bb0085","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1210\/jcem-27-10-1418","article-title":"Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment","volume":"27","author":"S\u00f6nksen","year":"1967","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0090","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1056\/NEJM199004053221405","article-title":"Acromegaly","volume":"322","author":"Melmed","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ghir.2015.07.002_bb0095","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1210\/jc.2012-2896","article-title":"The metabolic profile in active acromegaly is gender-specific","volume":"98","author":"Ciresi","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11102-011-0365-5","article-title":"Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study","volume":"15","author":"Giordano","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2015.07.002_bb0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2337\/diacare.19.3.287","article-title":"Insulin resistance and body fat distribution","volume":"19","author":"Yamashita","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ghir.2015.07.002_bb0110","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ghir.2015.07.002_bb0115","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35053000","article-title":"The hormone resistin links obesity to diabetes","volume":"409","author":"Steppan","year":"2001","journal-title":"Nature"},{"issue":"Suppl.","key":"10.1016\/j.ghir.2015.07.002_bb0120","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1507\/endocrj.46.Suppl_S17","article-title":"Interaction between leptin and growth hormone (GH)\/IGF-I axis","volume":"46","author":"Isozaki","year":"1999","journal-title":"Endocr. J."},{"key":"10.1016\/j.ghir.2015.07.002_bb0125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1210\/jcem.85.1.6296","article-title":"Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery","volume":"85","author":"Damjanovi\u0107","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2265.2001.01180.x","article-title":"Effect of Sandostatin LAR on serum leptin levels in patients with acromegaly","volume":"54","author":"Tan","year":"2001","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.ghir.2015.07.002_bb0135","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/BF03349161","article-title":"Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy","volume":"26","author":"Baldelli","year":"2003","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.ghir.2015.07.002_bb0140","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/meta.2001.24882","article-title":"Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination","volume":"50","author":"P\u00e1ramo","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.ghir.2015.07.002_bb0145","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1530\/EJE-10-0344","article-title":"Influence of pegvisomant on serum ghrelin and leptin levels in acromegalic patients","volume":"163","author":"Roemmler","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2015.07.002_bb0150","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1046\/j.1365-2265.2003.01795.x","article-title":"The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly","volume":"59","author":"Parkinson","year":"2003","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.ghir.2015.07.002_bb0155","first-page":"CR685","article-title":"Serum leptin levels in acromegaly\u2014a significant role for adipose tissue and fasting insulin\/glucose ratio","volume":"8","author":"Bolanowski","year":"2002","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ghir.2015.07.002_bb0160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1530\/eje.0.1380086","article-title":"Serum leptin and insulin concentrations in patients with insulinoma before and after surgery","volume":"138","author":"Popovic","year":"1998","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2015.07.002_bb0165","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2337\/dc06-1581","article-title":"Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance","volume":"30","author":"Fern\u00e1ndez-Real","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ghir.2015.07.002_bb0170","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.1097243","article-title":"Visfatin: a protein secreted by visceral fat that mimics the effects of insulin","volume":"307","author":"Fukuhara","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ghir.2015.07.002_bb0175","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1210\/jc.2009-0474","article-title":"A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly","volume":"94","author":"Sucunza","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0180","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/BF03345660","article-title":"Growth hormone\/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to short-term fasting in acromegaly","volume":"31","author":"Grottoli","year":"2008","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.ghir.2015.07.002_bb0185","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1210\/jc.2002-021808","article-title":"Serum resistin (FIZZ3) protein is increased in obese humans","volume":"88","author":"Degawa-Yamauchi","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0190","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1210\/jc.2003-031410","article-title":"Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects","volume":"89","author":"Heilbronn","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0195","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2265.2003.01789.x","article-title":"Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance","volume":"58","author":"Silha","year":"2003","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.ghir.2015.07.002_bb0200","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2310\/JIM.0b013e3182823390","article-title":"Resistin and leptin levels in acromegaly: lack of correlation with echocardiographic findings","volume":"61","author":"Gurbulak","year":"2013","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.ghir.2015.07.002_bb0205","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1210\/endo.143.6.8947","article-title":"Growth hormone rapidly induces resistin gene expression in white adipose tissue of spontaneous dwarf (SDR) rats","volume":"143","author":"Delhanty","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.ghir.2015.07.002_bb0210","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ghir.2015.07.002_bb0215","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(03)12255-6","article-title":"Adiponectin and protection against type 2 diabetes mellitus","volume":"361","author":"Spranger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ghir.2015.07.002_bb0220","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/jc.2012-2103","article-title":"Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults","volume":"98","author":"Kizer","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0225","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1210\/jc.2003-032023","article-title":"Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess","volume":"89","author":"Lam","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0230","first-page":"3476","article-title":"Effect of growth hormone (GH) on serum concentration of leptin: study in patients with acromegaly and GH deficiency","volume":"83","author":"Miyakawa","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0235","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1530\/eje.0.1500663","article-title":"Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients","volume":"150","author":"Ronchi","year":"2004","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2015.07.002_bb0240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/bbrc.1999.0255","article-title":"Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity","volume":"257","author":"Arita","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ghir.2015.07.002_bb0245","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1161\/01.ATV.20.6.1595","article-title":"Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients","volume":"20","author":"Hotta","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ghir.2015.07.002_bb0250","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.maturitas.2014.06.008","article-title":"Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome","volume":"79","author":"Chedraui","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.ghir.2015.07.002_bb0255","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cell.2014.06.005","article-title":"Adipsin is an adipokine that improves \u03b2 cell function in diabetes","volume":"158","author":"Lo","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ghir.2015.07.002_bb0260","first-page":"213","article-title":"Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass","volume":"18","author":"Napolitano","year":"1994","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.ghir.2015.07.002_bb0265","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1210\/jc.2008-2086","article-title":"Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly","volume":"94","author":"Higham","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0270","first-page":"727","article-title":"Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review","volume":"28","author":"Ertorer","year":"2007","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.ghir.2015.07.002_bb0275","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1210\/jc.2006-2276","article-title":"The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly","volume":"92","author":"Lindberg-Larsen","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2015.07.002_bb0280","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1365-2265.2003.01876.x","article-title":"Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment","volume":"59","author":"Baldelli","year":"2003","journal-title":"Clin. Endocrinol. (Oxf)"}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637415300137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637415300137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:49:00Z","timestamp":1761086940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637415300137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1096637415300137"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2015.07.002","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2015.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}